Core Company Information - Precipio, Inc. is a specialty cancer diagnostics company focused on addressing cancer misdiagnoses through innovative diagnostic products and services [4] - The company aims to improve diagnostic accuracy, laboratory workflow, and patient outcomes, ultimately reducing healthcare expenses [4] Upcoming Corporate Update - Precipio will host its Q1-2025 corporate update call on May 15, 2025, at 5:00 PM ET, which will cover updates on the company's core businesses [1] - Participants can access the call by dialing 844-695-5519 for domestic calls or 1-412-902-6760 for international calls [2] Engagement and Communication - Listeners can submit questions in advance via email to investors@precipiodx.com, and management will address these during the call [3] - A replay of the call will be available approximately 24 hours after the event on Precipio's Investors page [3] Additional Information - For more information, stakeholders can visit Precipio's website or follow the company on social media platforms [5]

Financial Data and Key Metrics Changes - In Q4, the company achieved positive and adjusted EBITDA along with positive cash flow, marking a significant milestone towards profitability [9] - Revenue growth for Q4 was nearly 26% compared to the same quarter of the previous year, while full-year revenue growth was close to 22% [14] Business Line Data and Key Metrics Changes - The pathology division's revenues exceeded the breakeven point of $1.3 million per month for the second consecutive quarter, with a target run rate of approximately $25 million by the end of 2025 [16] - The products division's Q4 revenues remained stable at $700,000, with ongoing customer onboarding processes affecting revenue recognition [17][18] Market Data and Key Metrics Changes - The company anticipates a gradual increase in revenue share generated through its distributor network versus direct sales, aiming for scalable growth [37] Company Strategy and Development Direction - The company aims to shift its mindset from a defensive to an offensive approach, viewing expenditures as investments for future growth [13] - A revitalized distribution strategy is in place to create new opportunities for scalable growth beyond direct sales [44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming challenges related to regulatory changes, equipment processes, and personnel issues, emphasizing a proactive approach to customer onboarding [31][32] - The company is focused on enhancing visibility within financial markets and aims to provide clearer insights into its growth trajectory [40][42] Other Important Information - The return of Steve Miller as Chief Commercial Officer is expected to accelerate growth in the products division, leveraging his extensive background in the diagnostic field [35] Q&A Session Summary - No specific questions or answers were provided in the content, thus this section is not applicable.

Core Company Update - Precipio, Inc. will host its Q4 and year-end 2024 corporate update call on March 31, 2025, at 5:00 PM ET, providing updates on its core businesses [1] - The conference call can be accessed via specific phone numbers for domestic and international callers, with an option for pre-registration [2] Investor Engagement - Listeners can submit questions in advance via email, and management will address these during the call [3] - A replay of the call will be available approximately 24 hours after the event on Precipio's Investors page [3] Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to reduce cancer misdiagnoses through innovative diagnostic products and services [4] - The company develops technologies in its laboratory to improve diagnostic outcomes and commercializes these as proprietary products for the global laboratory community [4] Additional Information - For more information, stakeholders are encouraged to visit Precipio's website and follow the company on social media platforms [5]

Core Insights - Precipio, Inc. has achieved significant financial milestones in Q4 2024, indicating its ability to attain financial independence through positive cash flow from its pathology service division [1][2][3] - The company reported an Adjusted EBITDA of $0.4 million for Q4 2024, marking a positive operational performance [6] - Precipio experienced an increase of $0.3 million in cash during Q4 2024, primarily driven by cash flow from operations [6] Financial Performance - The company reported a net loss of $0.3 million for Q4 2024, with an Adjusted EBITDA of $0.4 million after accounting for non-cash stock-based compensation and other significant expenses [5][6] - The reconciliation of financial metrics shows that EBITDA was $0 for the quarter, highlighting the impact of non-cash costs on profitability [5][6] Management Commentary - The CEO emphasized that ending 2024 with positive financial results is a crucial step for the company, allowing it to focus on growth and value creation without relying on external capital [3] - Management believes that the current cash reserves and growth pipeline position the company to become profitable in the near future [2][3] Company Overview - Precipio is a healthcare biotechnology company specializing in cancer diagnostics, aiming to reduce misdiagnoses through innovative diagnostic products and services [7] - The company develops and commercializes proprietary technologies to improve diagnostic accuracy and laboratory workflow, ultimately enhancing patient outcomes [7]

NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced that options granted to senior management on January 14 would vest when the 10-day VWAP of the Company's common stock exceeds $30.30 per share – a level 5x greater than the option exercise price, the closing price from Tuesday, January 14. These options have no time-based vesting; if the performance above is not met, the options will not vest. The Compensation Committee approved t ...

Financial Data and Key Metrics - The company crossed the 10,000 case mark for the year, compared to close to 8,000 in 2023 [7] - Q3 pathology revenues reached $4.5 million, an 18% increase from Q2 [9] - Q3 Products division revenues increased by 13% over Q2, reaching $680,000 [13] - Cash burn reduced by 75% from approximately $1 million in Q3 2023 to $226,000 in Q3 2024 [19] Business Line Performance - Pathology division exceeded breakeven for the second consecutive quarter, with a goal to reach a $20 million run rate [9] - Products division is progressing towards breakeven, with three key customers in onboarding stages expected to significantly impact performance [13] - Products division is expected to become the main growth engine due to recurring revenue, customer retention, and higher margins [14][15] Market and Strategic Direction - The company aims to achieve breakeven in 2024, avoiding dilutive capital raises and focusing on organic growth [8] - Pathology division serves as a self-sustained cost-free R&D platform, supporting future product development [10] - The company plans to leverage distribution channels for product sales, increasing revenue share from distributors [17][18] Management Commentary on Environment and Outlook - Management is confident in achieving financial independence and building cash reserves through organic growth [20][21] - The company plans to enhance investor education and visibility through investor conferences, analyst coverage, and consistent performance [25][26] - Management anticipates ending the year strong and entering the next year with even stronger performance [27] Other Important Information - The company’s sales team consists of five members in the pathology division and three in the products division, with potential hiring for additional stability [11][16] - The majority of revenues are currently from direct sales, but a gradual shift towards distributor-generated revenue is expected [17] Q&A Session - No specific questions or answers were provided in the transcript [31]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-17893 ...

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of th ...

NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely competitive industry is key to ensuring the company's continued growth and ...

NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in Q2 due to the impact of the Change Healthcare hack, as previously described. With ca ...